Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Area of Science:

• Hepatobiliary Medicine
• Oncology
• Prognostic Biomarkers

Background:

• Advanced hepatocellular carcinoma (HCC) prognosis is influenced by cancer stage and liver dysfunction.
• Multiple staging systems exist, but optimal prediction of survival remains unclear.

Purpose of the Study:

• To evaluate and compare the accuracy of various cancer staging systems for predicting survival in advanced HCC patients.
• To identify the most effective staging system for this patient population.

Main Methods:

• Retrospective analysis of 187 advanced HCC patients treated at Memorial Sloan-Kettering Cancer Center.
• Comparison of seven staging systems: TNM 6th ed., Okuda, Barcelona Clinic Liver Cancer (BCLC), Cancer of the Liver Italian Program (CLIP), Chinese University Prognostic Index (CUPI), Japan Integrated Staging (JIS), and Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire (GETCH).
• Survival prediction accuracy assessed using concordance index (c-index); independent prognostic variables identified.

Main Results:

• CLIP, CUPI, and GETCH demonstrated the highest accuracy in predicting patient survival.
• BCLC and TNM 6th edition showed poor prognostic discrimination.
• Performance status, AST, abdominal pain, and esophageal varices enhanced CLIP's discriminatory ability.

Conclusions:

• CLIP, CUPI, and GETCH are the most informative staging systems for advanced HCC survival prediction in this cohort.
• BCLC and TNM 6th edition are not supported by these data for predicting survival.
• Further prospective validation is needed to confirm the clinical utility of CLIP, CUPI, and GETCH for patient stratification and treatment decisions.